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Objectives: We sought to describe the presentation, course, and 
outcomes of hospitalized pediatric coronavirus disease 2019 
patients, with detailed description of those requiring mechanical 
ventilation, and comparisons between critically ill and noncritical 
hospitalized pediatric patients.
Design: Observational cohort study.
Setting: Riley Hospital for Children at Indiana University Health in 
Indianapolis in the early weeks of the coronavirus disease 2019 
pandemic.
Patients: All hospitalized pediatric patients with confirmed coro-
navirus disease 2019 as of May 4, 2020, were included.
Interventions: Patients received therapies including hydroxychlo-
roquine, remdesivir, tocilizumab, and convalescent serum and 
were managed according to an institutional algorithm based on 
evidence available at the time of presentation.
Measurements and Main Results: Of 407 children tested for se-
vere acute respiratory syndrome-coronavirus 2 at our hospital, 24 
were positive, and 19 required hospitalization. Seven (36.8%) 
were critically ill in ICU, and four (21%) required mechanical ven-
tilation. Hospitalized children were predominantly male (14, 74%) 
and African-American or Hispanic (14, 74%), with a bimodal distri-
bution of ages among young children less than or equal to 2 years 
old (8, 42%) and older adolescents ages 15–18 (6, 32%). Five 
of seven (71.4%) of critically ill patients were African-American 
(n = 3) or Hispanic (n = 2). Critical illness was associated with 
older age (p = 0.017), longer duration of symptoms (p = 0.036), 
and lower oxygen saturation on presentation (p = 0.016); with 
more thrombocytopenia (p = 0.015); higher C-reactive protein 
(p = 0.031); and lower WBC count (p = 0.039). Duration of me-
chanical ventilation averaged 14.1 days. One patient died.
Conclusions: Severe, protracted coronavirus disease 2019 is 
seen in pediatric patients, including those without significant 
comorbidities. We observed a greater proportion of hospitalized 
children requiring mechanical ventilation than has been reported 
to date. Older children, African-American or Hispanic children, 
and males may be at risk for severe coronavirus disease 2019 
requiring hospitalization. Hypoxia, thrombocytopenia, and ele-
vated C-reactive protein may be useful markers of critical illness. 
Data regarding optimal management and therapies for pediatric 
coronavirus disease 2019 are urgently needed. (Pediatr Crit Care 
Med 2020; XX:00–00)
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While children are at lower risk for severe disease, they can experience morbidity and mortality due to coronavirus disease 2019 (COVID-19) (1). Mod-
els project between 3.7 and 37 million children could develop 
COVID-19 by the end of 2020 (2). There are limited pediatric 
clinical data. The objective of this observational study is to de-
scribe the demographics, clinical presentation, and outcomes to 
date of hospitalized pediatric COVID-19 patients in the earli-
est weeks of the pandemic. The hospital courses of those me-
chanically ventilated are described in detail. We then sought to 
compare demographics and clinical presentation of critically ill 
children to children who were hospitalized but not critically ill.
MATERIALS AND METHODS
This report includes all patients with confirmed COVID-19 
hospitalized at Riley Hospital for Children at Indiana Univer-
sity Health in Indianapolis, as of May 4, 2020. Testing for se-
vere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
in Indiana began February 26, and the first confirmed case was 
March 6 (3). Critical illness was defined as requiring admission 
to the PICU. All COVID-19 patients had an infectious disease 
consultation. Institutional treatment guidelines at the time 
considered hydroxychloroquine, and remdesivir if available via 
compassionate use. Tocilizumab was available for patients with 
cytokine storm. Convalescent serum was available for some. 
Standardized laboratories were obtained. Oxygenation satura-
tion index (OSI) was calculated with the following formula (4): DOI: 10.1097/PCC.0000000000002511
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(mean airway pressure × Fio
2
 × 100) ÷ peripheral oxygen sat-
uration. Data were abstracted from medical records after the 
study was deemed exempt from review by the Institutional Re-
view Board at Indiana University.
Statistical analyses included Fisher exact test for categorical 
variables, Mann-Whitney U test for continuous nonparametric 
variables, and t test for continuous normally distributed variables. 
p value of less than 0.05 was considered significant. Analysis was 
completed using StataSE 14.2 (StataCorp, College Station, TX).
RESULTS
At the time of writing, 24 out of 407 children tested positive 
for SARS-CoV-2 at our hospital. Nineteen pediatric COVID-
19 patients required hospitalization. Seven were critically ill, 
with four requiring intubation (Fig. 1). Demographics, comor-
bidities, and presenting symptoms stratified by critical illness 
are presented (Table 1). Comorbidities were present in two 
intubated patients: one had cerebral palsy and restrictive lung 
disease and the other had an elevated body mass index and 
new-onset diabetic ketoacidosis.
As compared to other hospitalized patients with pediatric 
COVID-19, those who developed critical illness had longer 
duration of symptoms (p = 0.036) and significantly lower ox-
ygen saturation on room air (p = 0.016) on presentation. The 
critically ill also had significantly more thrombocytopenia 
(p = 0.015), and higher C-reactive protein (CRP) (p = 0.031). 
WBC was significantly lower in critically ill patients (p = 0.039), 
although interquartile ranges (IQRs) were within normal 
range for both groups. Five patients had coinfections with 
other respiratory viruses, including rhinovirus/enterovirus 
(n = 2), human coronavirus NL63 (n = 1), respiratory syncytial 
virus (n = 1), and parainfluenza virus (n = 1). These included 
three critically ill (3/6, 50%) and two noncritical patients (2/9, 
22%; p = 0.33). All critically ill patients had abnormal chest ra-
diograph findings compared with 56% of noncritical patients; 
however, there was no statistical significance.
Of the critically ill, three patients were treated with high 
flow nasal cannula and had an uneventful PICU course. Four 
patients required intubation (Fig. 1), with three intubated 
within 24 hours of presentation due to hypoxia. The fourth 
presented in new-onset diabetic ketoacidosis/hyperosmolar 
hyperglycemia. He initially tested negative for SARS-CoV-2, 
was intubated on hospital day 4, and tested positive for SARS-
CoV-2 at that time. Duration of mechanical ventilation aver-
aged 14.1 days. All critically ill patients were initially treated 
Figure 1. PICU course for mechanically ventilated pediatric coronavirus disease 2019 patients. Summary of additional details specific to intubated 
patients: A, Adolescent African-American male with no past medical history. Required mechanical ventilation for 15 d and hospitalized for a total of 20 d. 
Initial interleukin (IL)-6 level 9 pg/mL (normal < 5 pg/mL). B, Adolescent white male with history of cerebral palsy and restrictive lung disease. Required 
mechanical ventilation for 24 d and hospitalized for a total of 36 d. Initial IL-6 level 32 pg/mL. C, Infant African-American male with no past medical 
history. Required mechanical ventilation for 11 d and hospitalized for a total of 20 d. Initial IL-6 level 11 pg/mL. D, Adolescent African-American male with 
elevated body mass index presenting with new-onset diabetic ketoacidosis. Required mechanical ventilation for 7 d and hospitalized for a total of 11 d.  
Initial IL-6 level less than 5 pg/mL. This patient died after sudden cardiac arrest. CRP = C-reactive protein, OSI = oxygenation saturation index.
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TABLE 1. Demographic, Clinical and Laboratory Characteristics, and Clinical Course for 
Hospitalized Patients to Date
Characteristics
Critically Ill,  
n = 7
General Ward,  
n = 12
Total,  
n = 19 p
Demographics and clinical characteristics on presentation, n (%)
 Age, yr, median (IQR) 16 (7–17) 1.8 (0.4–5) 5 (0.8–16) 0.017
  ≤ 2 1 (14) 7 (58) 8 (42)  
  3–14 2 (29) 3 (25) 5 (26)  
  15–18 4 (57) 2 (17) 6 (32)  
 Male sex 7 (100) 7 (58) 14 (74) 0.11
 Race/ethnicity    0.75
  White 2 (29) 2 (17) 4 (21)  
  African-American 3 (43) 4 (33) 7 (37)  
  Hispanic 2 (29) 5 (42) 7 (37)  
  Asian 0 (0) 1 (8) 1 (5)  
 Racial/ethnic minority 5 (71) 10 (83) 15 (79) 0.60
 Comorbiditiesa 3 (43) 5 (42) 8 (42) 0.999
 Presenting symptoms
  Fever 5 (71) 7 (58) 12 (63) 0.66
  Dyspnea 5 (71) 7 (58) 12 (63) 0.66
  Chest pain 2 (29) 2 (17) 4 (21) 0.60
  Cough 3 (43) 2 (17) 5 (26) 0.27
  Emesis 1 (14) 2 (17) 2 (16) 0.999
  Sore throat 1 (14) 1 (8) 2 (11) 0.999
  Dysgeusia and/or anosmia 2 (29) 1 (8) 3 (16) 0.52
 Days of symptoms before presentation, 
median (IQR)
4 (3–14) 1 (0.5–3.5) 3 (1–4) 0.036
 Peripheral oxygen saturation on room air 
within 24 hr of time of SARS-CoV-2 
testing, median (IQR)
86% (78–96) 98% (95.5–99) 96% (88–99) 0.016
Critically Illb 
n = 6
General Ward 
n = 8
Totalb 
n = 14 p
Initial laboratories and imaging results within 24 hr of time of SARS-CoV-2 testing, median (IQR)
 WBC (K/cumm) 5.7 (4.7–7.1) 8.5 (7.3–12.1) 7.4 (5.8–9.6) 0.039
 Platelets (K/cumm) 133 (94–224) 339 (216–356) 246 (137–339) 0.014
 Thrombocytopenia, n (%) 4 (66) 0 (0) 4 (29) 0.015
 n = 6 n = 7 n = 13  
 ANC 4 (3.1–4.8) 4.9 (4.5–11.9) 4.7 (3.9–5.2) 0.15
 Neutropenia by ANC, n (%) 0 (0)  3 (43) 3 (23) 0.12
 ALC 0.75 (0.4–1.2) 1.7 (1.5–2.7) 1.5 (0.8–2.4) 0.085
 Lymphopenia by ALC, n (%) 3 (50) 1 (14) 4 (29) 0.27
 C-reactive protein (mg/dL) 11.5 (8.1–16) 3.6 (0.5–6) 5.7 (1.1–9.7) 0.031
 Ferritin (ng/mL) 193 (142–367) 219 (36–327) 205 (139–327) 0.57
(Continued)
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with broad-spectrum antibiotics until diagnosis of COVID-
19 was confirmed. Cultures from blood and other specimens 
were obtained at admission to rule out bacterial infection as 
appropriate.
Therapies, including pharmacologic and supportive care, 
are outlined in Figure 1. Remdesivir was considered for all 
mechanically ventilated patients; two received it. One patient 
did not qualify, and the other was not given remdesivir due to 
acute kidney injury and mild rhabdomyolysis from hyperos-
molar hyperglycemia.
These critically ill patients had complicated courses. One 
patient, treated with remdesivir, developed transaminitis (al-
anine transaminase 290 U/L and aspartate transaminase 1,271 
U/L) and significant rhabdomyolysis (creatine kinase 55,360 
U/L) with peak values the day after completing remdesivir. Two 
patients developed secondary bacterial infections. One patient 
developed increased hypoxia and hypothermia after 14 days 
of ventilation; respiratory culture demonstrated Pseudomonas 
aeruginosa. He was treated with cefepime and nebulized tobra-
mycin. Another patient failed extubation after 8 days of ventila-
tion; respiratory culture demonstrated Haemophilus influenzae 
and Moraxella catarrhalis. He was treated with amoxicillin-cla-
vulanate. One patient died after sudden cardiac arrest. His CRP 
and ferritin improved after receiving tocilizumab and conva-
lescent sera, however, on day 6 of mechanical ventilation (hos-
pital day 11), he developed a nonperfusing junctional rhythm, 
then ventricular tachycardia, and was unable to be resuscitated. 
Cause of death remains unclear and a postmortem examina-
tion was not performed.
DISCUSSION
We describe characteristics, critical care courses, and com-
parisons among hospitalized pediatric COVID-19 patients, in-
cluding seven with critical illness, during the early weeks of the 
pandemic at a U.S. children’s hospital. These initial findings 
deserve further exploration in larger studies. We noted severe 
COVID-19 disease for some patients, with a greater propor-
tion of hospitalized children requiring mechanical ventila-
tion (21.5%) than has been reported to date. These included 
patients without comorbidities. We also experienced a pedi-
atric death related to COVID-19.
At the time of diagnosis with SARS-CoV-2, critically ill 
patients had symptoms for a longer period of time and were sig-
nificantly more hypoxic, thrombocytopenic, and inflamed. Per 
international reports, mechanical ventilation for children with 
COVID-19 is rare with only one in the Coronavirus Infection 
in Pediatric Emergency Departments (CONFIDENCE) study 
(1%), two in Lombardy, Italy (0.1%), and 13 out of 2,141 in 
China (5–7). U.S. hospitals have reported lower proportions of 
intubated critically ill pediatric COVID-19 patients and fewer 
ventilated days (8, 9). Thrombocytopenia was associated with 
critical illness and has been described as an early finding in 
patients with COVID-19 (10). Thrombocytopenia is suspected 
to be multifactorial and could be due to cytokine storm or di-
rect effects of SARS-CoV-2 on bone marrow, host immunity, 
or lung parenchyma (11). Consistent with a Chinese study, 
CRP was elevated in 10 of 13 children (12), and in our cohort, 
higher CRP was associated with critical illness. WBC was lower 
in critically ill patients, although the IQRs for both groups 
were within normal. Our center appears to have a greater pro-
portion of pediatric cases requiring mechanical ventilation 
than is reported elsewhere (5–9). Further research is needed to 
understand factors associated with critical illness and mechan-
ical ventilation for pediatric COVID-19.
We note that the clinical and laboratory findings in criti-
cally ill children with COVID-19 in this study (decreased ox-
ygen saturation, thrombocytopenia, and elevated CRP) are 
also seen in children with bacterial sepsis (13, 14). Thus, the 
present study does not provide clinical findings or biomarkers 
 Lactate dehydrogenase (U/L) 329 (247–432) 359 (275–472) 353 (261–452) 0.63
 d-dimer (ng/mL) 212 (200–755) 278 (200–390) 212 (200–418) 0.80
 n = 6 n = 9 n = 15  
 Presence of coinfection by respiratory 
viral panelc, n (%)
3 (50) 2 (22) 5 (33) 0.33
 Abnormal chest radiograph within 24 hr of 
SARS-CoV-2 testingd, n (%)
6 (100) 5 (56) 11 (73) 0.10
ALC = absolute lymphocyte count, ANC = absolute neutrophil count, IQR = interquartile range, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
a Presence of clinical comorbidities such as asthma (n = 3), obesity (n = 2), hematological disorder (n = 2), and restrictive lung disease (n = 1).
b Patient with new diagnosis of T-cell ALL in blast crisis excluded from laboratory, radiological, and hospital course analysis.
c Presence of respiratory coinfections by respiratory viral panel polymerase chain reaction testing: rhino/enterovirus (n = 2), coronavirus NL63 (n = 1), respiratory 
syncytial virus (n = 1), and parainfluenza (n = 1).
d Presence of chest radiograph findings such as opacities with bilateral opacities (n = 7) or unilateral opacities (n = 4).
Boldface entries are those with a statistical significance (p < 0.05).
TABLE 1. (Continued). Demographic, Clinical and Laboratory Characteristics, and Clinical 
Course for Hospitalized Patients to Date
Characteristics
Critically Illb,  
n = 6
General Ward,  
n = 6
Total,  
n = 12 p
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that might distinguish critical COVID-19 from sepsis. Typical 
management for these critical cases includes broad-spectrum 
antimicrobials while SARS-CoV-2 testing and bacterial cul-
tures are pending.
The CRP and OSI of the four intubated patients improved 
with various therapies. The most striking improvements were 
noted in patients 2 and 4 following tocilizumab, convalescent 
sera, and prone positioning. The OSI for patients 1 and 3 did 
improve after starting remdesivir, although CRP did not. This 
difference, of unclear clinical significance, could be due to the 
tocilizumab targeting the IL-6 receptor and causing mitigation 
of the cytokine cascade, while remdesivir and convalescent 
plasma target SARS-CoV-2. With a small number of ventilated 
patients and three of four having received a combination of 
therapies, it is challenging to investigate the role of any single 
therapy.
The death of patient 4 occurred unexpectedly. His CRP and 
ferritin improved after receiving tocilizumab and convalescent 
sera, however, his d-dimer gradually rose compared with the 
other three patients. Although there has been a concern for 
thrombotic events in patients with COVID-19, this patient was 
on anticoagulation at the time with a therapeutic anti-Xa of 0.5 
international units/mL.
Certain demographics appear to be associated with critical 
illness in pediatric COVID-19. Although there was one criti-
cally ill infant in our cohort, older children appear more likely 
to have critical illness. Most patients in our report were male 
(73.7%), and all critically ill patients were male. A slight male 
predominance among children with COVID-19 has been re-
ported out of Italy (57%, CONFIDENCE study), the United 
States (52–57%), and China (56.6%) (6–9, 15). By contrast, 
eight of 10 infants with COVID-19 were female in another 
Chinese report (16). Larger pediatric studies could better de-
fine whether risk of severe COVID-19 in the United States is 
increased in male children.
Limited data currently exist on racial/ethnic disparities 
among hospitalized pediatric COVID-19 patients. In this re-
port, 74% of hospitalized pediatric COVID-19 patients and five 
of seven critically ill children (71%) were African-American 
or Hispanic. Indiana’s population is 85.1% Caucasian, 9.8% 
African-American, and 7.1% Hispanic (17). Thus, both 
moderate and severe COVID-19 disproportionately affected 
African-American and Hispanic children. Given the few sig-
nificant comorbidities in our report, disparities may point 
to greater risks for acquiring SARS-CoV-2 among African-
American and Hispanic children. Structural racism underlies 
wide health inequities in the United States (18) and must be 
addressed in the COVID-19 pandemic, including impacts of 
the pandemic on children of color.
Limitations of this report include the small number of 
patients, which limits the conclusions that may be drawn. 
Additionally, some mild cases did not have laboratories com-
pleted due to a combination of an average 12-hour turnaround 
in SARS-CoV-2 testing and rapid clinical improvement, lead-
ing to same-day discharges from the hospital. We note, how-
ever, key observations that may inform other pediatric centers 
and should prompt investigation in larger studies. Although 
these data come from review of medical records, an institu-
tional algorithm and infectious disease consultation on each 
case supported consistent documentation.
CONCLUSIONS
Severe, protracted COVID-19 disease is seen in pediatric 
patients, including those without significant comorbidities. 
Older children, African-American or Hispanic children, and 
males may be at risk for severe COVID-19 requiring hospital-
ization. Hypoxia, thrombocytopenia, and elevated CRP may 
be useful markers of critical illness. Larger studies are needed 
to examine associations with severe COVID-19 in pediatrics. 
Data regarding optimal management and therapies for pedi-
atric COVID-19 are urgently needed.
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